Effects of inhaled prostaglandins E1, E2, and F2alpha on the airway resistance of healthy and asthmatic man.
1. Changes in specific airway conductance after the inhalation of aerosols of prostaglandins (PG) E1, E2, and F2alpha were investigated in healthy and asthmatic subjects. 2. Inhalation of 155 nmol (55 mug) of PGE1 or 156 nmol (55 mug) of PGF2 resulted in consistent minor bronchodilatation in healthy subjects, but in asthmatic patients airway conductance increased significantly, along with subjective improvement. Isoprenaline (988 nmol; 550 mug) inhalation resulted in a similar increase in conductance to that obtained after these two prostaglandins, whereas a control aerosol had no effect. In contrast to the isoprenaline aerosol, both PGE1 and PGF2 were highly irritant to inhale. It was concluded that this made them unsuitable for therapeutic use. 3. Prostaglandin F2alpha inhalation resulted in a dose-related bronchoconstriction in healthy and asthmatic subjects. Asthmatics were approximately 150 than were the healthy subjects but there was very wide and significant variantion in the sensitivity of the asthmatic subjects. In contrast the asthmatic subjects were only 8-5 times more sensitive to histamine than the healthy subjects with less variation in response of individual subjects. The reasons for the hyper-reactivity of asthmatic subjects to PGF2alpha is unknown and no correlation could be drawn between increased sensitivity and age, type of asthma, or treatment. 4. The effects of disodium cromoglycate, flufenamic acid, atropine methonitrate, PGF2 and isoprenaline on PGF2alpha-induced bronchoconstriction were investigated in healthy subjects. Prostaglandin E2 reversed PGF2alpha-induced bronchoconstriction, as did isoprenaline, but prior treatment with the other drugs had no effect in preventing bronchoconstriction.
D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000403:Airway Resistance / Q000187:drug effects*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D006632:Histamine / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011458:Prostaglandins E / Q000494:pharmacology / Q000627:therapeutic use*; D011460:Prostaglandins F / Q000494:pharmacology / Q000627:therapeutic use*; D012044:Regression Analysis; D012138:Respiratory Therapy
D000336:Aerosols; D011458:Prostaglandins E; D011460:Prostaglandins F; D006632:Histamine; D007545:Isoproterenol